[11C]DPA-713([11C]DPA-713) - 药物靶点：TSPO_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

靶点

TSPO

作用机制

TSPO调节剂(TSPO蛋白调节剂)、PET imaging(正电子发射断层成像术增强剂)

治疗领域

其他疾病

在研适应症-

非在研适应症

诊断试剂

原研机构

University of Sydney Union

在研机构-

非在研机构

CEA-Léti

University of Sydney Union

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C21H26N4O2

InChIKeyILZWUAWCTNWSFZ-SFIIULIVSA-N

CAS号868072-18-8

关联

2

项与 [11C]DPA-713 相关的临床试验

JPRN-UMIN000024167 / RecruitingN/AIIT

Analysis of corresponding neuropathology of localization-related epilepsy by PET using an inflammatory ligand, [11C]-DPA713 - Analysis of neuropathology of localization-related epilepsy using an inflammatory radio-isotope ligand

开始日期2016-11-01

申办/合作机构

Ministry of Education Science and Technology, Korea

NCT01793532 / CompletedN/AIIT

Assessment of [11C]DPA-713 in Temporal Lobe Epilepsy

Background:
- Some people with epilepsy have an epileptic focus, a small part of the brain that is the starting point of the seizure. This focus is like an irritant or an inflammation, and helps cause the seizure. People with epilepsy that affects the temporal lobe of the brain often have an epileptic focus. Researchers want to look at the epileptic focus by using a drug that attaches to a protein associated with inflammation. An imaging study with the drug will show how much inflammation is in the area of the brain where the seizures start. The drug, called [11C]DPA-713, will be tested for its effectiveness in people with temporal lobe epilepsy. Its effects will be compared with imaging studies given to healthy volunteers.
Objectives:
- To see if [11C]DPA-713 can show the inflammation in the epileptic focus of seizures.
Eligibility:
Individuals at least 18 years of age who have temporal lobe epilepsy.
Healthy volunteers at least 18 years of age.
Design:
Participants will have three outpatient visits to the National Institutes of Health Clinical Center. The visits will last from 2 to 5 hours.
Participants will be screened with a physical exam, neurological exam, and medical history. Blood samples will be collected before the start of the study.
Participants will have a positron emission tomography (PET) scan. This scan will be used to look at brain chemistry and function. The study drug will be given during the scan to see how well it shows points of inflammation in the brain. Some participants will provide additional blood samples during the PET scan.
Participants will also have a magnetic resonance imaging (MRI) scan. This scan will look at the structure of the brain.

开始日期2013-01-31

申办/合作机构

National Institute of Mental Health

100 项与 [11C]DPA-713 相关的临床结果

登录后查看更多信息

100 项与 [11C]DPA-713 相关的转化医学

登录后查看更多信息

100 项与 [11C]DPA-713 相关的专利（医药）

登录后查看更多信息

11

项与 [11C]DPA-713 相关的文献（医药）

2019-09-01·Journal of Neurology2区 · 医学

In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer’s disease

2区 · 医学

Article

作者: Yoshikawa, Etsuji ; Higuchi, Makoto ; Ouchi, Yasuomi ; Ando, Ichiro ; Shimada, Hitoshi ; Suhara, Tetsuya ; Terada, Tatsuhiro ; Bunai, Tomoyasu ; Yokokura, Masamichi ; Obi, Tomokazu

OBJECTIVENeuronal damage and neuroinflammation are important events occurring in the brain of Alzheimer's disease (AD). The purpose of this study was to clarify in vivo mutual relationships among abnormal tau deposition, neuroinflammation and cognitive impairment in patients with early AD using positron emission tomography (PET) with [¹¹C]PBB3 and [¹¹C]DPA713.METHODSTwenty patients with early AD and 20 age-matched normal control (NC) subjects underwent a series of PET measurements with [¹¹C]PBB3 for tau aggregation and [¹¹C]DPA713 for microglial activation (neuroinflammation). Inter- and intrasubject comparisons were performed regarding the levels of [¹¹C]PBB3 binding potential (BP_ND) and [¹¹C]DPA713 BP_ND in the light of cognitive functions using statistical parametric mapping (SPM) and regions of interest (ROIs) method.RESULTSThe [¹¹C]PBB3 BP_ND was greater in the temporo-parietal regions of AD patents than NC subjects, and a similar increasing pattern of [¹¹C]DPA713 BP_ND was observed in the same patients. Correlation analyses within the AD group showed a positive direct correlation between [¹¹C]PBB3 BP_ND and [¹¹C]DPA713 BP_ND in the parahippocampus. Pass analysis revealed that cognitive impairment was more likely linked to the level of the parahippocampal [¹¹C]PBB3 BP_ND than that of [¹¹C]DPA713 BP_ND.CONCLUSIONSThe pattern of abnormal tau deposition was very similar to that of neuroinflammation in patients with early-stage AD. Specifically, the direct positive correlation of tau pathology with neuroinflammation in the parahippocampus suggests that neuronal damage in this region is closely associated with microglial activation. Consistently, tau aggregation in this region matters more than neuroinflammation regarding the cognitive deterioration in AD.

2018-03-01·Journal of Neuroimmune Pharmacology3区 · 医学

The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site

3区 · 医学

Article

作者: Stathis, Marigo ; Coughlin, Jennifer M ; Pomper, Martin ; Slusher, Barbara S ; Rojas, Camilo

[¹¹C]-PK11195 (PK11195) has been widely used with positron emission tomography (PET) to assess levels of the translocator protein 18 kDa (TSPO) as a marker of neuroinflammation. Recent ligands, such as [¹¹C]-PBR28 and [¹¹C]-DPA713, have improved signal-to-noise ratio and specificity for TSPO over PK11195. However, these second generation radiotracers exhibit binding differences due to a single polymorphism (rs6971) that leads to three genotypes: C/C, C/T and T/T associated with high, mixed and low binding affinities, respectively. Here we report that [³H]-DPA-713 in the presence of cholesterol or PK11195 has an accelerated dissociation rate from TSPO in platelets isolated from individuals with the T/T genotype. This allosteric interaction was not observed in platelets isolated from individuals with the C/C or C/T genotype. The results provide a molecular rationale for low binding affinity of T/T TSPO and further support the exclusion of these subjects from PET imaging studies using second generation TSPO ligands.

2017-03-01·Journal of Cerebral Blood Flow & Metabolism2区 · 医学

Depiction of microglial activation in aging and dementia: Positron emission tomography with [¹¹C]DPA713 versus [¹¹C](R)PK11195

2区 · 医学

Article

作者: Yokokura, Masamichi ; Iwata, Yasuhide ; Futatsubashi, Masami ; Nakaizumi, Kyoko ; Takebayashi, Kiyokazu ; Ouchi, Yasuomi ; Mori, Norio ; Terada, Tatsuhiro ; Suzuki, Katsuaki ; Yoshikawa, Etsuji ; Bunai, Tomoyasu

The presence of activated microglia in the brains of healthy elderly people is a matter of debate. We aimed to clarify the degree of microglial activation in aging and dementia as revealed by different tracers by comparing the binding potential (BPND) in various brain regions using a first-generation translocator protein (TSPO) tracer [11C]( R)PK11195 and a second-generation tracer [11C]DPA713. The BPND levels, estimated using simplified reference tissue models, were compared among healthy young and elderly individuals and patients with Alzheimer’s disease (AD) and were correlated with clinical scores. An analysis of variance showed category-dependent elevation in levels of [11C]DPA713 BPND in all brain regions and showed a significant increase in the AD group, whereas no significant changes among groups were found when [11C]( R)PK11195 BPND was used. Cognito-mnemonic scores were significantly correlated with [11C]DPA713 BPND levels in many brain regions, whereas [11C]( R)PK11195 BPND failed to correlate with the scores. As mentioned elsewhere, the present results confirmed that the second-generation TSPO tracer [11C]DPA713 has a greater sensitivity to TSPO in both aging and neuronal degeneration than [11C]( R)PK11195. Positron emission tomography with [11C]DPA713 is suitable for the delineation of in vivo microglial activation occurring globally over the cerebral cortex irrespective of aging and degeneration.

100 项与 [11C]DPA-713 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
诊断试剂	临床1期	-	University of Sydney Union	-
诊断试剂	临床1期	-	CEA-Léti	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2014	N/A	癫痫	-	[11C]DPA-713	襯繭淵遞積壓觸淵築鑰(齋壓齋積鹽築憲觸顧繭) = 鹽襯襯窪憲衊淵壓餘範餘獵餘夢積願鏇鏇製蓋 (鹹願鏇鬱糧憲觸壓遞醖 )	-	2014-11-05
				[11C]PBR28[11C]DPA-713 ([11C]PBR28)	襯繭淵遞積壓觸淵築鑰(齋壓齋積鹽築憲觸顧繭) = 簾廠鑰壓淵醖窪壓膚艱餘獵餘夢積願鏇鏇製蓋 (鹹願鏇鬱糧憲觸壓遞醖 )